AmpliPhi Biosciencess C3J Logo

Armata has joined together two seasoned drug development teams, AmpliPhi Biosciences and C3J Therapeutics, to tackle the global and increasingly serious threat of antimicrobial-resistant bacterial infections. Driven by rigorous and innovative science, Armata is developing high-impact, best-in-class bacteriophage therapeutics with the potential to save millions of lives.

Armata Pharmaceuticals
Enter

Knowledge Library

Bacteriophage Therapy

Jul
11
2017
Jul
10
2017

Antibiotic Resistance Crisis

Sep
19
2017
May
05
2015
Review on Antimicrobial Resistance
The Wellcome Trust and the UK Department of Health